Contract With Customer, Asset, Potential Development Milestone Payments, Maximum

No definition available.

Name:	ovid_ContractWithCustomerAssetPotentialDevelopmentMilestonePaymentsMaximum
Namespace Prefix:	ovid_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Contract With Customer, Asset, Potential Sales Milestone Payments, Maximum

+ References

No definition available.

+ Details

Name:	ovid_ContractWithCustomerAssetPotentialSalesMilestonePaymentsMaximum
Namespace Prefix:	ovid_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Intellectual Property Rights, Assignment Agreement, Minimum Beneficial Ownership Percentage

+ References

No definition available.

+ Details

Name:	ovid_IntellectualPropertyRightsAssignmentAgreementMinimumBeneficialOwnershipPercentage
Namespace Prefix:	ovid_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Intellectual Property Rights, Assignment Agreement, Minimum Beneficial Ownership Percentage, Expiration Threshold, Antidilution Right

+ References

No definition available.

+ Details

Name:	ovid_IntellectualPropertyRightsAssignmentAgreementMinimumBeneficialOwnershipPercentageExpirationThresholdAntidilutionRight
Namespace Prefix:	ovid_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Intellectual Property Rights, Assignment Agreement, Minimum Equity Sales by Investee, Expiration Threshold, Antidilution Right

+ References

No definition available.

+ Details

Name:	ovid_IntellectualPropertyRightsAssignmentAgreementMinimumEquitySalesByInvesteeExpirationThresholdAntidilutionRight
Namespace Prefix:	ovid_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Global commercial and regulatory milestone payments.

+ References

No definition available.

+ Details

Name:	ovid_LicenseAgreementMilestonePayments
Namespace Prefix:	ovid_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Percentage Of Potential Royalties

+ References

No definition available.

+ Details

Name:	ovid_PercentageOfPotentialRoyalties
Namespace Prefix:	ovid_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Revenue, Remaining Performance Obligation, Variable Consideration Amount

+ References

No definition available.

+ Details

Name:	ovid_RevenueRemainingPerformanceObligationVariableConsiderationAmount
Namespace Prefix:	ovid_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Royalty Licensing And Termination Agreement, Rights Sold Or Licensed To Counterparty, Percentage Of Global Rights

+ References

No definition available.

+ Details

Name:	ovid_RoyaltyLicensingAndTerminationAgreementRightsSoldOrLicensedToCounterpartyPercentageOfGlobalRights
Namespace Prefix:	ovid_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Royalty Monetization Liability, Noncurrent

+ References

No definition available.

+ Details

Name:	ovid_RoyaltyMonetizationLiabilityNoncurrent
Namespace Prefix:	ovid_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Royalty Revenue, Upon Regulatory Approval, Percentage Of Sales, Maximum

+ References

No definition available.

+ Details

Name:	ovid_RoyaltyRevenueUponRegulatoryApprovalPercentageOfSalesMaximum
Namespace Prefix:	ovid_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront Payment, Number Of Shares Received As Payment, Assignment Agreement

+ References

No definition available.

+ Details

Name:	ovid_UpfrontPaymentNumberOfSharesReceivedAsPaymentIntellectualPropertyAssignmentAgreement
Namespace Prefix:	ovid_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(24))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_AccruedRoyaltiesCurrentAndNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

+ Details

Name:	us-gaap_CommonStockSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-11

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-2

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of investment in equity security without readily determinable fair value.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-2

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 321
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479536/321-10-50-3

+ Details

Name:	us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of investment in equity method investee and investment in and advance to affiliate.

+ References

+ Details

Name:	us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.

+ References

No definition available.

+ Details

Name:	us-gaap_OperatingCostsAndExpenses
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, beyond the current operating cycle.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-12

+ Details

Name:	us-gaap_ProceedsFromSaleOfLongtermInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=ovid_LigandPharmaceuticalsIncorporatedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=ovid_MarinusPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=ovid_NewCoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=ovid_TakedaPharmaceuticalCompanyLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ovid_NewCoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=ovid_SeriesSeedConvertiblePreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ovid_GravitonBioscienceCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

COLLABORATION AND LICENSE AGREEMENTS (Details) - USD ($)		1 Months Ended					3 Months Ended		6 Months Ended		12 Months Ended
	May 31, 2026	May 31, 2026	Jun. 30, 2025	Jun. 30, 2025	Feb. 28, 2025	Mar. 31, 2021	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Dec. 31, 2025	Jan. 31, 2025	Oct. 31, 2023	Apr. 30, 2023	Mar. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue							$ 733,000	$ 6,272,000	$ 733,000	$ 6,402,000
Royalty monetization liability							872,000		872,000		$ 872,000	$ 0
Fair value of series seed shares							$ 42,694,000		$ 42,694,000		$ 42,694,000	$ 41,961,000
Common stock shares issued (in shares)							184,755,735		184,755,735		184,755,735	130,184,353
Common stock, par value (in dollars per share)							$ 0.001		$ 0.001		$ 0.001	$ 0.001
Sale of long-term investment					$ 70,000
Royalty expense			$ 7,000,000.0	$ 6,300,000							$ 700,000
Ligand Pharmaceuticals Incorporated
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement milestone payments (up to)														$ 30,000,000.0
Marinus Pharmaceuticals, Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock shares issued (in shares)																123,255
Common stock, par value (in dollars per share)																$ 0.001
Related Party
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accrued royalties	$ 900,000	$ 900,000
Related Party \| NewCo
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum potential development milestone payments	7,500,000	7,500,000
Maximum potential sales milestone payments	287,000,000.0
Fair value of series seed shares	$ 700,000	$ 700,000
Related Party \| Takeda Pharmaceutical Company Limited
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of global rights						50.00%
Nonrefundable upfront payment						$ 196,000,000.0
Eligible consideration upon achieving milestones						$ 660,000,000.0
Maximum percentage of royalties (up to)						20.00%
Total revenue							$ 0	0	$ 0	0
Related party transaction expenses recognized							0	$ 0	0	$ 0
Related Party \| Ligand Pharmaceuticals Incorporated
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of potential royalties	13.00%	13.00%												13.00%
Related Party \| Minimum \| NewCo
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of potential royalties	31.40%	31.40%
Related Party \| Maximum \| NewCo
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of potential royalties	37.70%	37.70%
Collaborative Arrangement, Co-promotion \| Related Party \| Ligand Pharmaceuticals Incorporated
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty monetization liability													$ 0
NewCo
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Fair value of series seed shares							$ 733,000		$ 733,000		$ 733,000
NewCo \| Related Party
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Minimum beneficial ownership percentage		5.00%
Antidilution right, expiration threshold, percentage of convertible stock sold		25.00%
Antidilution right, expiration threshold, minimum equity sales		$ 40,000,000.0
NewCo \| Related Party \| Series Seed Convertible Preferred Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares of series seed convertible preferred stock	740,000	740,000
Graviton Bioscience Corporation \| Series A Preferred Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase of preferred stock															$ 10,000,000.0